Skip to content

Study · In vitro (cells) · 2016

5 results

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide.

Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K, Mortensen B, Serin G, Mirjolet JF, Bichat F, Rekdal Ø

Journal of medicinal chemistry29 Mar 2016Cited by 88 (Europe PMC)

PMID26982623 (opens in a new tab)DOI10.1021/acs.jmedchem.5b02025 (opens in a new tab)PepBankPUB-26982623
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cancer cell testing, LTX‑315 showed superior anticancer activity among the identified peptides.

    In plain wordsIn cells, LTX‑315 showed stronger anticancer activity than the other identified peptides.

    Peptide
    LTX-315
    Outcome
    IncreaseAnticancer activity
    Study

    n: not reported in source

    Comparator
    other identified peptides
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among these peptides, LTX-315 displayed superior anticancer activity and was selected as a lead candidate.
  2. 02LabIn vitro (cell-free)Pharmacokinetics

    In laboratory testing, LTX‑315 showed relatively high plasma protein binding.

    In plain wordsIn lab tests, LTX‑315 showed relatively high binding to plasma proteins.

    Peptide
    LTX-315
    Outcome
    Not applicablePlasma protein binding
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This peptide showed relative high plasma protein binding abilities and a human plasma half-life of 160 min, resulting in formation of nontoxic metabolites.
  3. 03LabIn vitro (cell-free)Pharmacokinetics

    In human plasma, LTX‑315 had a half-life of 160 min.

    In plain wordsIn lab tests with human plasma, LTX‑315 had a half-life of 160 min.

    Peptide
    LTX-315
    Outcome
    Not applicablePlasma half-life
    Study

    humann: not reported in source

    human plasma
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    half-life
    160 min
    human plasma

    Source sentences

    Summary
    This peptide showed relative high plasma protein binding abilities and a human plasma half-life of 160 min, resulting in formation of nontoxic metabolites.
  4. 04LabIn vitro (cell-free)Safety outcome

    In laboratory testing, LTX‑315 breakdown produced nontoxic metabolites.

    In plain wordsIn lab tests, LTX‑315 breakdown produced nontoxic metabolites.

    Peptide
    LTX-315
    Outcome
    Not applicableMetabolite toxicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This peptide showed relative high plasma protein binding abilities and a human plasma half-life of 160 min, resulting in formation of nontoxic metabolites.
  5. 05LabIn vitro (cell-free)Activity measurement

    In laboratory testing, LTX‑315 had relatively low ability to inhibit CYP450 enzymes.

    In plain wordsIn lab tests, LTX‑315 had relatively low ability to inhibit CYP450 enzymes.

    Peptide
    LTX-315
    Outcome
    Not applicableCYP450 inhibition
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, the lead candidate demonstrated relatively low ability to inhibit CYP450 enzymes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.